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A waxing gibbous moon illuminates the tortuous trail as mountaineers climb up Adam’s 
glacier, towards the summit of Mt Adams, in the Cascade Range, Washington. The moon, a 
reminder that this journey is a passing phase. 
 

















Whatever road I take I’m going home…
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ABSTRACT 
Most individuals will experience one or more extremely traumatic events during their 
lifetime. For the most part, humans are resilient and have a tremendous capacity to bounce 
back from hardships; however, for a critical minority, trauma can result in debilitating 
symptoms, including posttraumatic stress disorder (PTSD). Historically, sleep disturbance 
and inflammation were viewed as symptoms or consequences of PTSD; however, recently 
there has been a shift towards conceptualizing sleep disturbance and inflammation as early 
indications of mental health issues to come. This thesis examined the inextricable link 
between stress, sleep, and inflammation, and how gaining a better understanding of these 
interconnected systems could be harnessed to develop enhanced treatments for populations 
with stress-related symptoms and disorders. 
 
Study I investigated the effect of standardized sleep therapy on posttraumatic stress 
symptoms, as well as the gene expression pathways that may mediate this effect in sleep 
disturbed military service members with PTSD (n =39) and controls without PTSD (n = 
27). At baseline, participants diagnosed with insomnia and/or obstructive sleep apnea 
received a combination of 4 to 8 biweekly sessions of cognitive behavioral therapy for 
insomnia (CBT-I), and automatic positive airway pressure therapy. Results indicated that 
22.6% of participants with PTSD had clinically meaningful posttraumatic stress symptom 
reduction following standardized sleep therapy. Posttraumatic stress symptoms were linked 
to increased expression of genes associated with immune response systems, which were 
downregulated with symptom reduction at follow-up. 
 
In order to investigate alternative interventions that may improve sleep quality and 
potentially provide additional benefits for stress-related disorders, Study II was a meta-
analysis to determine the effect of mindfulness meditation on sleep quality outcomes in 
sleep disturbed adults with various mental and physical health conditions. To assess for 
relative efficacy, mindfulness meditation was compared to evidence-based sleep treatments 
(like CBT-I and medication) and time/attention-matched interventions to control for 
placebo effects, which were analyzed separately. The results indicated that mindfulness 
meditation had a similar effect on sleep quality compared to the evidence-based sleep 
treatments and was superior to the time/attention matched placebo controls. However, the 
strength of this evidence was low to moderate, so some doubt remains. 
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Once mindfulness meditation was established as a potential intervention to improve sleep 
quality, Study III investigated if sleep quality improvements, following a 4-week 
mindfulness-based integrative medicine program, were associated with reductions in 
posttraumatic stress, anxiety, depression, and postconcussion symptoms in sleep disturbed 
military service members with mild traumatic brain injury (n = 93). The secondary aim was 
to determine if sleep quality improvements were associated with decreases in protein levels 
of inflammation. Results indicated that sleep quality improvements, following the 
intervention, were linked to reductions in posttraumatic stress and other neurobehavioral 
symptoms, but not to inflammation. Moreover, 65.8% of participants with PTSD had 
clinically meaningful posttraumatic stress symptom reduction at follow-up. 
 
While we found some evidence that posttraumatic stress symptoms were reduced following 
the mindfulness-based integrative medicine program, this program required almost 30 
treatment hours. This may be an excessive treatment duration when mindfulness meditation 
is used in populations with less severe symptoms. As such, Study IV investigated the effect 
of a brief 5-week (7.5-hour) mindfulness meditation program on perceived stress symptoms 
in moderately stressed healthcare professionals. Participants were randomized to the 
mindfulness-based self-care (MBSC) group (n = 43) or the life-as-usual control group (n = 
35). Results indicated that the meditation group had larger reductions in perceived stress, 
and these reductions were maintained two months following the completion of the program. 
 
Taken together, the findings of these four studies led to some important conclusions 
regarding the link between stress, sleep, and inflammation. While mindfulness research is 
still in its infancy, these preliminary results suggest that mindfulness meditation is effective 
in improving sleep in adult populations with various mental and physical health conditions 
(Study II). Less intense mindfulness meditation programs (7.5 hours) may be beneficial to 
reduce perceived stress, which could potentially prevent the development of more severe 
mental health conditions (Study IV). While 22.6% of individuals with PTSD had reduced 
posttraumatic stress symptoms following standardized sleep therapy (Study I), 65.8% of 
individuals with PTSD had reduced posttraumatic stress symptoms following the 
mindfulness-based integrative medicine program (Study III). There was some evidence 
that a relationship exists between sleep quality improvements, decreases in gene expression 
levels of inflammation, and reductions in posttraumatic stress symptoms; although the 
direction of causality cannot be determined (Study I and III). Clinical implications and 
recommendations for future research will be discussed. 
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1 INTRODUCTION 
Pain and suffering are inextricable experiences of the human condition. Most individuals 
will experience one or more extremely traumatic events during their lifetime; however, 
there is significant variability that governs subsequent responses to these events.1 For the 
most part, humans are resilient and have a tremendous capacity to bounce back from 
hardships.2 However, for a critical minority, trauma can result in debilitating symptoms that 
impact multiple dimensions of functioning and quality of life.3 What explains these 
differences and how can these symptoms best be treated, or better yet be prevented? The 
answer is only partly understood, but burgeoning evidence points to sleep and inflammation 
as key players in the pathogenesis and maintenance of stress-related disorders. 
 
1.1 STRESS 
In 1950, Hans Selye first defined stress from a biological perspective as a nonspecific 
response of the body to any demand made upon it (e.g., exercise, extreme temperatures).4 
Not all scientists agreed with Selye’s definition; they argued that if the stress response was 
nonspecific then everyone should react the same way to the same stressor.5 In the 1960s, 
cognitive processes were integrated into the biological model of stress to resolve this 
discrepancy. It was determined that individual differences in perception account for these 
diverse responses to a stressor—stress is not what happens to you, but how you respond to 
it.6 Despite this reconciliation, there are a number of universal conditions that elicit a stress 
response in almost everyone: novelty, unpredictability, and loss of control.7 The terms 
eustress (i.e., good stress) and distress (i.e., toxic stress) were later introduced to distinguish 
the stress response triggered by a positive event from a negative event (Figure 1).8,9 
 
 
Figure 1 | The human function curve. Eustress improves performance, creativity, and growth. 
Meanwhile, distress causes fatigue and exhaustion followed by the onset of mental and physical 
health conditions, which impede performance. Adapted from “The human function curve: a 
paradigm for our times”, by P.G. Nixon, 1982, Activitas Nervosa Superior, p. 133. 
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1.1.1 Effects of acute stress 
When an event is perceived as a stressor, the brain and body recruit a range of complex 
systems to maintain homeostasis.10 This adaptive stress response is called allostasis—
achieving stability through change.11 The first phase of the stress response is initiated by the 
central nervous system, whereby physical stressors (e.g., viral infections) are mainly 
processed by the brainstem and limbic regions, and psychosocial stressors (e.g., public 
speaking) are largely processed by the executive, affective, and salience networks, 
including the prefrontal cortex, amygdala, and hippocampus.12-14 Next, the autonomic 
nervous system is activated, namely, the sympathetic–adrenal–medullary (SAM) axis, 
which culminates in the release of epinephrine and norepinephrine (collectively 
catecholamines) into the bloodstream by the adrenal medulla.15 Then the hypothalamic-
pituitary-adrenal (HPA) axis is activated, in which corticotropin-releasing hormone (CRH) 
is secreted from the paraventricular nucleus in the hypothalamus.16 This elicits the secretion 
of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland, prompting the 
synthesis and release of glucocorticoids (cortisol in humans) into the bloodstream by the 
adrenal cortex.16	The increase of circulating catecholamines and glucocorticoids coordinates 
widespread changes in vast systems (e.g., immune, cardiovascular, metabolic) to protect 
and prepare the body for a fight-or-flight response.17 Once the perceived stressor has 
passed, feedback loops are triggered in various systems (e.g., from the adrenal gland to the 
hypothalamus) to terminate the stress response and restore homeostasis.18 
 
1.1.2 Effects of chronic stress 
When the stress response becomes prolonged or excessive, it can put wear and tear on the 
brain and body (i.e., allostatic overload) and cause alterations in physical, cognitive, 
emotional, and behavioral functioning (Figure 2).19 Within the immune system, a persistent 
influx in glucocorticoids may result in glucocorticoid receptor resistance, which in turn, 
interferes with the downregulation of inflammation.20 The combination of HPA axis 
dysregulation and increased inflammation might converge with other brain and body 
systems to contribute to psychiatric and immune-mediated disorders (e.g., autoimmune, 
cardiovascular, metabolic).21,22 The brain not only can affect the immune system, but the 
immune system can affect the brain; this bi-directional communication can result in 
increased neuroinflammation under chronic stress.23 Increased neuroinflammation while 
initially adaptive, if left unchecked can result in aberrant functional and structural changes 
in brain regions key to memory and emotional regulation.24,25 For example, acute stress 
often enhances memory—a possible survival mechanism to help remember a dangerous 
Stress, Sleep, and Inflammation 
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situation—however, chronic stress often impairs memory function.26,27 Prolonged stress can 
increase the risk for burnout—a syndrome defined by symptoms of emotional exhaustion 
and depersonalization.28,29 If excessive, early life stress may increase the risk for impaired 
social skills, aggression, addiction (e.g., food, nicotine, alcohol, drugs), and posttraumatic 
stress disorder (PTSD) in adulthood.30-33 
 
 
Figure 2 | Biological systems involved in the pathophysiology of chronic stress. In the brain, 
chronic stress may result in functional changes in brain circuits (for example, in executive, 
affective, and salience networks), structural changes in brain volumes (for example, in the 
hippocampus), and increased neuroinflammation. Beyond the brain, chronic stress impairs 
feedback regulation of the hypothalamic-pituitary-adrenal (HPA) axis. Within the immune system, 
there is evidence of increased levels of circulating cytokines and low-grade activation of innate 
immune cells, including monocytes. The combination of HPA axis dysregulation and increased 
inflammation might converge with other brain and body systems to contribute to psychiatric and 
immune-mediated disorders. The sequence of events leading to changes in these interconnected 
systems is not known; however, alterations in the stress response system can, directly and 
indirectly, affect the brain and other body systems, which suggests a bidirectional link. ACTH, 
adrenocorticotropin; CRH, corticotropin-releasing hormone; IL, interleukin; NK, natural killer; 
TNF, tumor necrosis factor. Adapted from “Major depressive disorder”, by C. Otte, et al., 2016, 
Nature Reviews Disease Primers, 2, p. 8. © 2016 by Macmillan Publishers Limited, part of 
Springer Nature. Adapted with permission. 
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1.2 POSTTRAUMATIC STRESS DISORDER 
Posttraumatic stress reactions have roots stretching back centuries and were widely known 
to previous generations as combat fatigue, shell shock, soldier’s heart, or war neurosis.34 
However, it was not until 1980 that PTSD became a household name and was officially 
recognized in the third edition of the Diagnostic and Statistical Manual of Mental Disorder 
(DSM-III).35 Since then our understanding of PTSD has grown significantly; nonetheless, 
the field of traumatic stress is still riddled with controversy over the actual diagnostic 
features of PTSD, its causation, and what constitutes evidence-based treatment.36-38 
 
1.2.1 Diagnostic features 
Currently, there are two recognized definitions of PTSD—the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5), published in 2013 by the American 
Psychiatric Association, and the International Classification of Diseases, 11th Revision 
(ICD-11), released in 2018 by the World Health Organization (Table 1). Both PTSD 
definitions require that the individual witnesses or experiences firsthand an extremely 
traumatic event (e.g., actual/threatened death, severe injury, or sexual violence). If that 
criterion is met, the DSM-5 requires the manifestation of at least one of five intrusion 
symptoms, one of two avoidance symptoms, two of seven alterations in cognitions and 
mood, and two of six alterations in arousal and reactivity.39 Instead, the ICD-11 requires the 
manifestation of at least one of two intrusion symptoms, one of two avoidance symptoms, 
and one of two alterations in arousal and reactivity.40 These symptoms must persist for at 
least one month, cause clinically significant distress or impairment in social, occupational, 
or other key areas of functioning, and not be attributed to the effects of a substance (e.g., 
alcohol, medication) or another medical condition (e.g., hypothyroidism, seizure).39 
 
1.2.2 Diagnostic discrepancies 
Historically, the DSM and ICD have been concordant with their PTSD definitions. 
However, in the latest revisions, the DSM-5 expanded its scope to include three new 
symptoms, while the ICD-11, in a strategic effort to improve diagnostic accuracy, narrowed 
its focus to the core fear-based symptoms of PTSD.41,42 The effect of these modifications is 
clinically significant, as several studies report that more individuals are diagnosed with 
PTSD using the DSM-5 criteria compared with the ICD-11 criteria.43,44 Moreover, both 
definitions identify different individuals as having PTSD.45 Another concern surrounds the 
inherent virtues of the two diagnostic definitions. On one side, the DSM-5 criteria apply to 
a larger population of trauma-exposed individuals with more diverse symptoms; however, 
Stress, Sleep, and Inflammation 
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the inclusion of broader symptoms may increase the rate of misdiagnosing other mental 
health conditions as PTSD.45-50 This has serious implications for making treatment 
recommendations and for the discovery of meaningful biomarkers.51 
 







INTRUSION 1. Repeated, disturbing, and unwanted memories of the 
stressful experience 
Ö Ö  
2. Repeated, disturbing dreams of the stressful experience Ö Ö Ö 
3. Suddenly feeling or acting as if the stressful experience 
were happening again 
Ö Ö Ö 
4. Feeling very upset when something reminded you of the 
stressful experience 
Ö Ö  
5. Having strong physical reactions when something 
reminded you of the stressful experience 
Ö Ö  
AVOIDANCE 1. Avoiding memories, thoughts, or feelings related to the 
stressful experience 
Ö Ö Ö 
2. Avoiding external reminders of the stressful experience Ö Ö Ö 
ALTERATIONS 
IN MOOD AND 
COGNITION 
1. Trouble remembering important parts of the stressful 
experience 
Ö Ö  
2. Having strong negative beliefs about yourself, other 
people, or the world 
 Ö  
3. Blaming yourself or someone else for the stressful 
experience or what happened after it 
 Ö  
4. Having strong negative feelings such as fear, horror, 
anger, guilt, or shame 
 Ö  
5. Loss of interest in activities you used to enjoy Ö Ö  
6. Feeling distant or cut-off from other people Ö Ö  





1. Irritable behavior, angry outbursts, or acting 
aggressively 
Ö Ö  
2. Taking too many risks or doing things that could cause 
you harm 
Ö Ö  
3. Being “super alert” or watchful or on-guard Ö Ö Ö 
4. Feeling jumpy or easily startled Ö Ö Ö 
5. Having difficulty concentrating Ö Ö  
6. Trouble falling or staying asleep Ö Ö  
Symptoms are reproduced from the PTSD Checklist for DSM-5, a 20-item self-report measure 
that assesses the presence and severity of PTSD symptoms. The ‘Avoidance’ and ‘Alterations in 
Mood and Cognition’ symptom clusters are combined into one Avoidance/Numbing symptom 
cluster for the DSM-IV. DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, 
International Classification of Diseases; PTSD, posttraumatic stress disorder 
 
1.2.3 Prevalence 
The 2014 World Mental Health Survey reported 12-month PTSD prevalence rates at 1.1% 
across all respondents (N = 51,295), and at 4.0% in respondents with trauma exposure (N = 
47,466).52,53 PTSD prevalence rates are significantly higher in high-income countries 
(compared to low), as well as in respondents exposed to sexual assault, physical assault, 
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and organized violence (compared to other trauma types).52,54 The 2014 National Health 
Study for a New Generation of U.S. Veterans (N = 20,563) reported PTSD prevalence rates 
at 13.5% across all military populations, at 15.7% in deployed veterans, and at 10.9% in 
nondeployed veterans.55 Prevalence estimates were higher in deployed men than deployed 
women (16.0% vs. 12.5%) but lower in nondeployed men than nondeployed women 
(10.5% vs. 12.3%).55 Other studies found sex differences across trauma type (Figure 3). For 
example, in the United States, the risk of developing PTSD is higher in men than women 
after rape (65.0% vs. 45.9%) but lower in men than women after a physical attack (1.8% vs. 
21.3%).56 These disparities may reflect sex and societal role differences that play into the 




Figure 3 | Sex differences in trauma exposure and posttraumatic stress disorder (PTSD) in 
the United States. (A) Lifetime prevalence of trauma exposure stratified by sex. (B) The 


































































B. Probability of a specific traumatic event being associated with PTSD, stratifed by sex
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1.2.4 Comorbidities 
Individuals who meet the criteria for one health condition more often meet the criteria for 
other health conditions—a phenomenon known as comorbidity. The National Comorbidity 
Survey (N = 5,877) found that over 88% of men and 79% of women with PTSD were 
diagnosed with at least one other mental health condition.56 The most common concurrent 
mental health diagnoses were major depression (37.2%), panic disorder (33.3%), social 
phobia (19.9%), and substance dependence (10.2%).58 Compared to individuals without 
PTSD, people with PTSD were at increased risk for autoimmune, cardiovascular, digestive, 
metabolic, musculoskeletal, and neurodegenerative disorders, as well as life-threatening 
infections.59-62 The elevated occurrence of comorbid conditions seen in PTSD is likely 
mediated by a combination of genetic and environmental factors; however, the precise 
contribution of these mediators is still widely unknown. There is also a substantial 
symptom overlap between PTSD and comorbid conditions—especially mild traumatic brain 
injury (mTBI) in military populations—so the high rate of comorbidity could partly result 
from an epiphenomenon of the diagnostic criteria.63 
 
1.3 SLEEP 
Sleep is an essential human behavior that is characterized by a reversible state of 
diminished receptiveness and loss of consciousness, which is typically initiated in a 
recumbent position with eyes closed.64 Recent advances in sleep research indicate that sleep 
may play a critical role in emotional regulation, cognitive function (including memory 
processing and consolidation), immune regulation, and brain waste removal.65,66 Adequate 
and quality sleep supports the functioning of almost every type of tissue and system in the 
body. Meta-analyses (Ns > 2,000,000) found that insufficient sleep (less than 7 hours) and 
prolonged sleep (more than 9 hours) were associated with increased risk for all-cause 
morbidity and cardiovascular events.67,68 Sleep is regulated by a two-process system 
comprised of sleep-wake homeostasis and circadian rhythms.69 Sleep-wake homeostasis 
means that sleep intensity and duration increases after a prolonged period without sleep.70 
In other words, the greater the sleep deficit, the greater the need to fall asleep and stay 
asleep longer. Circadian rhythms, on the other hand, modulate the timing of sleep. The 
central circadian clock is located in the suprachiasmatic nucleus, a small region of the brain 
in the hypothalamus. This system is responsible for imposing and synchronizing a close to 
24-hour rhythm on multiple bodily systems, including the proclivity to be awake or asleep 
at a particular time.70 
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1.3.1 Stages of sleep 
Sleep is divided into distinct stages marked by a discrete pattern of brain activity that can 
be measured by electroencephalography during polysomnography (i.e., sleep study). Rapid 
eye movement (REM) sleep and non-rapid eye movement (NREM) sleep are the two main 
stages of sleep. In humans, NREM sleep is further divided into three stages, N1, N2, and 
N3 (formerly stages 3 and 4), which correspond to a range of sleep depths.71 Stage N1 
marks the transition between wakefulness and sleep, which is typically followed by stage 
N2—collectively, these are lighter stages of sleep.72 Stage N3, also referred to as slow-
wave sleep (SWS) due to the preponderance of high-amplitude, low-frequency waves, is 
the deepest of all sleep stages.72 The fourth stage is REM sleep, brain activity during REM 
sleep resembles the waking brain and most dreaming occurs during this sleep stage.72 An 
average night of sleep contains four to six NREM-to-REM sleep cycles, in which each 
cycle lasts about 80 to 110 minutes.72 Stage N3 sleep (i.e., SWS) predominates during the 
first half of the night, while REM sleep increases as the night progresses (Figure 4A).72 The 
different stages of sleep are defined by specific brain oscillations measured by 
polysomnography (Figure 4B). For example, SWS sleep is characterized by slow 
oscillations (0.5-4 hertz), slow spindles (9-12 hertz), and fast spindles (12-15 hertz).73 
 
 
Figure 4 | Sleep architecture and sleep oscillations. (A) Human nocturnal sleep profile. (B) 
Theta oscillations are prominent during rapid eye movement (REM) sleep. Neocortical slow 
oscillations, thalamocortical spindles, and hippocampal ripples are signatures of non-rapid eye 
movement (NREM) sleep. Slow oscillations and spindles are hallmark features of slow-wave 
sleep (SWS). Adapted from “Mechanisms of systems memory consolidation during sleep”, by J. 
G. Klinzing, et al., 2019, Nature Neuroscience, 22, p. 1603. © 2019 by Springer Nature 
America, Inc. Adapted with permission. 
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1.3.2 Measurements of sleep 
Sleep quality is determined by a collection of sleep parameters, most commonly, total sleep 
time, sleep onset latency (the time it takes to fall asleep once in bed), wake after sleep onset 
(the time spent awake after initially falling asleep), and sleep efficiency (the percentage of 
time spent asleep while in bed).74 Sleep quality can be measured objectively (by 
instrument) or subjectively (by self-report). The most common objective measures used in 
clinical and research settings are the polysomnography and actigraphy. Traditionally, the 
laboratory-based polysomnography is considered the gold standard measure of sleep 
quality; however, it is impractical for long-term use and home utilization (e.g., resource-
demanding, difficult to use).75 During polysomnography, electrodes and sensors are placed 
on the body to monitor brain activity, muscle activity, eye movement, heart rhythm, 
respiratory rate, blood pressure, and blood oxygen levels. Actigraphy, on the other hand, is 
a watch-like device that measures gross motor activity from which estimates of sleep-wake 
patterns are made. Actigraphy has similar validity to polysomnography in assessing sleep 
parameters in healthy populations but tends to overestimate sleep quality in sleep disturbed 
populations.76 This is partly due to mischaracterizing states of laying still while awake as 
states of sleep.76 There are several questionnaires that measure subjective sleep quality 
retrospectively (e.g., over the past month) or diaries that measure subjective sleep quality 
prospectively (e.g., every night for the next week). The correlation between objective and 
subjective measures of sleep quality is low, which suggests that the two methods measure 
different dimensions of sleep.77 Still, other theories have suggested that individuals with 
insomnia experience ‘sleep state [mis]perception’—a trend to underestimate total sleep 
time and overestimate sleep onset latency.78,79 Nonetheless, subjective measures of sleep 
quality (compared to objective measures) seem to be better predictors of health outcomes in 
at least some clinical populations, including PTSD.80,81 
 
1.3.3 Link between sleep and posttraumatic stress 
Sleep disturbances, including difficulties initiating and maintaining sleep, are reported in 
over 70% of individuals with PTSD.82 Burgeoning evidence suggests that sleep disturbance 
is not merely a symptom of PTSD but instead plays a role in the development and 
maintenance of posttraumatic stress symptoms.83 Multiple longitudinal studies have 
indicated that pre-trauma or peri-trauma sleep disturbances contribute to the prediction of 
new-onset PTSD,84-89 with meta-analytic findings reporting that sleep disturbance yields a 
three-fold increased risk for anxiety.90 For example, in a longitudinal study of National 
Guard Soldiers (N = 522), predeployment daytime and nighttime sleep complaints 
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contributed to the prediction of new-onset PTSD at two years postdeployment.91 While 
sleep disturbance is reported to predict future PTSD, baseline posttraumatic stress 
symptoms did not predict subsequent sleep disturbance or even subsequent PTSD.92,93 
Evidence of polysomnography-measured sleep irregularities in PTSD were also found in 
two meta-analyses.94,95 The first study (N = 722) reported increased stage N1 sleep (i.e., 
light sleep) and decreased SWS (i.e., deep sleep) in participants with PTSD compared to 
controls.94 The second study (N > 2000) also reported decreased SWS, which was 
associated with PTSD symptom severity; however, no difference in stage N1 sleep was 
found.95 Accumulating evidence also supports the inhibition and/or disruption of REM 
sleep in the acute phase of PTSD, which hints at a possible pathogenic marker of symptom 
progression.96-100 Taken together, these findings demonstrate the interplay between sleep 
quality and PTSD; however, the extent to which posttraumatic stress symptoms can be 
mitigated by targeting sleep disturbance directly is less clear. 
 
1.4 INFLAMMATION 
The immune system is the body’s defense system against pathogens. Its main purpose is to 
identify and remediate internal and external threats like bacteria, fungi, parasites, viruses, 
and injury. Cells of the immune system circulate throughout the body and are roughly 
grouped into two systems: the innate immune system and the adaptive immune system. The 
innate immune system responds rapidly to threats upon the first encounter. Meanwhile, the 
adaptive immune system takes several days to respond but does so in a tailor-specific way 
that is sustained by memory cells that prime for threat reencounter.70 When the innate 
immune system detects a threat, it initiates a cascade of inflammatory responses to contain 
the spread of infection and stimulate healing to damaged tissue.101 The inflammatory 
mediators involved in these responses are cytokines, chemokines, prostaglandins, and 
vasoactive amines, which incite an array of processes aimed at restoring homeostasis.101 
Locally, these processes result in clinical signs of inflammation (i.e., redness, swelling, 
warmth, pain, and impaired function), rapid release of antimicrobials, and phagocytosis.70 
Systemically, these processes result in symptoms like fever and sickness behavior, which is 
characterized by anorexia, adipsia, anxiety, anhedonia, fatigue, pain sensitivity, sleep 
alterations, and social withdrawal.70,102 Under healthy conditions, acute inflammation is a 
protective mechanism for the body. On the other hand, when chronically sustained, 
inflammation can cause serious damage to the organism’s own tissues and organs, 
including the brain (Figure 5).103 
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Figure 5 | Brain milieu changes in response to chronic systemic inflammation. The main 
cells present in the brain are neurons, oligodendrocytes, astrocytes, and microglia. Under healthy 
conditions (left), neurons connect to each other through long axonal processes with synapses. 
Oligodendrocytes support axons with myelin sheaths. Astrocytes interact with blood vessels to 
form the blood-brain barrier and support neuronal synapses. Microglia form long processes that 
surveillance the brain and phagocytose apoptotic cells and prune inactive synapses without 
induction of inflammation. Under chronic inflammatory conditions (right), several mechanisms 
can lead to neurodegeneration. Peripheral immune cells and inflammatory molecules traverse the 
blood-brain barrier exerting direct and indirect neuronal cytotoxicity. Oligodendroglial myelin 
sheaths can be affected leading to axonal degeneration. An influx in astrocytes can lead to 
reduced blood-brain barrier and synaptic maintenance. An influx in microglia can lead to a pro-
inflammatory phenotype with reduced phagocytic and tissue maintenance functions. Adapted 
from “Systemic inflammation and the brain: novel roles of genetic, molecular, and 
environmental cues as drivers of neurodegeneration”, by R. Sankowski, et al., 2015, Frontiers in 
Cellular Neuroscience, 9, p. 4. © 2015 by Frontiers, Inc. Adapted with permission. 
 
1.4.1 Measurements of inflammation 
The most common methods to measure inflammation directly are to quantify protein 
biomarkers (e.g., C-reactive protein (CRP), proinflammatory cytokines) or the molecular 
biomarkers that regulate them (e.g., gene expression). Gene expression is the process by 
which information from a gene is used to direct the assembly of a protein (Figure 6). It is 
the fundamental process by which the genotype (i.e., genetic characteristic) gives rise to the 
phenotype (i.e., physical characteristic). Gene expression levels—the quantity of messenger 
RNA (mRNA) transcripts—are not static; these levels can be downregulated or upregulated 
dependent on genetic determinants, epigenetic modifications, and environmental factors, 
including stress and trauma exposure.104 Gene expression analysis is a laboratory technique 
that allows for the unbiased identification of dysregulated gene expression levels across the 
whole transcriptome in a target population.105 Dysregulated mRNA transcripts can then be 
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aggregated into networks and pathways based on their biological function (e.g., immune 
response pathway). However, a prominent problem of using gene expression analysis to 
measure inflammation in populations with psychiatric disorders is that individual gene 
expression differences are usually modest, which makes it difficult to distinguish true 
alterations from normal human variation. Some reasons for this include: mRNA transcripts 
can encode for several different proteins and the levels of mRNA transcripts do not always 
correspond with the levels of proteins they encode for.106 This makes protein biomarker 
analysis an important downstream complement to measure inflammation. While direct 
sampling of the brain is not readily assessable in living humans, protein biomarkers 
assessed in peripheral blood can provide a surrogate indicator of neuroinflammation in the 
brain.107 However, conclusions must be tempered since inflammation assessed in peripheral 
blood does not always correlate with cerebral spinal fluid levels,108 and peripheral blood 
levels may be subject to a blunted circadian rhythm.109,110 Nonetheless, the emerging role of 
biomarkers in psychiatry marks a retreat from a purely symptom-based diagnostic system, 
which is vulnerable to interpretation and subjective reporting. Moreover, the identification 
of biological systems associated with risk and symptom severity holds promise for the 
development of diagnostic tests, prognostic indicators, prophylactics, and treatments for 
trauma-exposed populations.111 
 
 Transcriptome: all RNA transcripts, 
including coding and non-coding 
 
Transcriptomics: the study of the 
transcriptome and its function 
 
Transcription: the process by which 
information in DNA is copied into 
an mRNA transcript 
 
Translation: the process by which 
protein is synthesized from 
information contained in an mRNA 
transcript 
 
Gene expression analysis: the 
quantification of mRNA transcripts 
 
Figure 6 | An overview of the flow of information from gene to protein in a human cell. 
First, both protein-coding and noncoding regions of DNA are transcribed into RNA. Some 
regions are removed (e.g., introns) during initial RNA processing. The remaining exons are then 
spliced together, and the spliced messenger RNA (mRNA) molecule (red) is prepared for export 
out of the nucleus through the addition of an endcap (sphere) and a polyA tail. Once in the 
cytoplasm, the mRNA can be used to construct a protein. Adapted from “Essentials of Cell 
Biology”, by C.M. O’Connor & J. U. Adams, 2010, NPG Education, Cambridge, MA. © 2010 
by Nature Education. Adapted with permission. 
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1.4.2 Link between inflammation and posttraumatic stress 
When stress is chronic, the immune system can become dysregulated, and proinflammatory 
cytokines [e.g., interleukin-1beta (IL-1β), interleukin-6 (IL-6), interferon-gamma (IFNγ), 
and tumor necrosis factor-alpha (TNF-α)] can increase in the periphery. These peripheral 
inflammatory mediators can communicate with the brain.23 Additionally, chronic stress can 
activate microglia (resident cells within the brain) and cause the release of inflammatory 
mediators, including proinflammatory cytokines, within the brain.112 Taken together, the 
consequences of these two processes may increase neuroinflammation and putatively 
contribute to the onset or severity of psychiatric symptoms.113,114 A 2015 meta-analysis (N 
= 1348), indicated that individuals with PTSD had increased blood levels of IL-1β, IL-6, 
and IFNγ compared with controls.115 Of note, these meta-analytic findings remained 
significant even after excluding studies that included participants with comorbid major 
depressive disorder from the analysis.115 Moreover, when studies with medication naive 
participants were exclusively analyzed, these same protein biomarkers plus levels of TNF-α 
were higher in individuals with PTSD compared to controls.115 This is particularly 
important given that major depressive disorder and medication use commonly occur with 
PTSD and are also associated with changes in levels of inflammation.116 A second 2018 
meta-analysis (N = 1077), which solely included studies with clinician diagnosed 
participants, reported that individuals with anxiety disorders, obsessive-compulsive 
disorder, and PTSD had elevated blood levels of IL-1β, IL-6, and TNF-α compared to 
healthy controls.117 Despite these findings, the observational design of the included studies 
restricted the meta-analyses from determining causal associations.118 Several studies also 
suggest molecular biomarkers that regulate the proinflammatory milieu in PTSD. For 
example, a mega-analysis of blood transcriptome studies (N = 511) found that the innate 
immune, cytokine, and type I interferon signaling pathways were associated with PTSD 
across all three case-control groups: men exposed to combat traumas, men exposed to 
interpersonal traumas, and women exposed to interpersonal traumas.119 Nevertheless, 
further work is needed to determine the extent to which these biomarkers can serve as 
specific and sensitive markers of posttraumatic stress symptoms. 
 
1.4.3 Link between inflammation and sleep 
The existence of a bidirectional relationship between sleep and the immune system is well- 
recognized—sleep helps regulate important immune functions, and the immune system 
regulates certain aspects of sleep.120 Although sleep plays an essential role in regulating the 
innate immune system, the evidence linking sleep to systemic inflammation is inconsistent. 
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This variability could be partly explained by the diverse parameters used in clinical trials to 
assess sleep quality (e.g., objectively measured, clinician assessed, or self-reported), as well 
as the duration of sleep deprivation (e.g., years, days, one night, or part of a night). In this 
respect, a recent meta-analysis (N > 50,000) of blood-based biomarkers found that 
subjectively measured sleep duration (i.e., clinician assessed or self-reported) was not 
associated with levels of CRP (n = 3490) or IL-6 (n = 2084).121 There was also no 
association between objectively measured sleep duration and levels of CRP (n = 1550); 
however, objectively measured short sleep durations were correlated with higher levels of 
IL-6 (n = 489).121 In studies that used a combination of objective and subjective measures, 
short sleep durations were correlated with higher levels of CRP (n = 5040) but were not 
associated with levels of IL-6 (n = 2573) or TNF-α (n = 157).121 A meta-analysis of 
experimental sleep deprivation studies found no evidence of altered levels of CRP (n = 
218), IL-6 (n = 263), or TNF-α (n = 109) following sleep restriction over 2 to 12 
consecutive days, for one night, or for part of a night—sleep was reduced from 8 hours to 4 
hours.121 Adding to these inconsistencies, partial sleep deprivation was shown to upregulate 
transcription of IL-6 and TNF-α mRNAs, while improved sleep quality following 
standardized sleep treatment was found to downregulate transcription of inflammatory-
related mRNAs.122-124 This highlights the variations of findings and the importance of 
utilizing a combination of objective and subjective sleep measures and analyzing both 
protein and molecular biomarkers to capture a more comprehensive picture of the 
relationship between sleep disturbance and inflammation. 
 
1.5 THESIS RATIONALE 
In 2017 the American Psychological Association published their most recent clinical 
practice guidelines for the treatment of adults with PTSD.125 Based on the strength of 
scientific evidence and patient preference, the guidelines recommended trauma-focused 
psychotherapy over pharmacotherapy as a first-line treatment for PTSD.125 At the heart of 
trauma-focused psychotherapy is imaginal and in vivo exposure to trauma reminders. This 
therapy is based on the premise that PTSD emerges due to the development of a fear-based 
memory.126 In theory, effective therapy involves correcting the pathological elements of the 
fear-based memory by first reactivating the memory so it is labile and then introducing new 
information that corrects the existing pathological components.127 While trauma-focused 
psychotherapies are efficacious for some patients, these treatments tend to be less effective 
in military populations.128 For example, between 30 to 51% of military service members do 
not demonstrate clinically meaningful symptom reduction, and remission rates are as low as 
Stress, Sleep, and Inflammation 
 15 
17 to 27%.129 Even when trauma-focused psychotherapy is combined with medication, no 
additional improvements are found.130,131 Thus, there is a need for improving existing 
PTSD treatments in military populations, with a better understanding of patient preference, 
disease mechanisms, and biomarkers underlying treatment response. This next section will 
briefly review the inextricable link between stress, sleep, and inflammation and alternative 
interventions that target these systems will be discussed. 
 
1.5.1 Link between stress, sleep, and inflammation 
Most people experience some type of adversity or trauma in their lifetime. The body is 
designed to activate the stress response system at low levels in response to these types of 
events.132 However, when there is sustained engagement of the stress response system, due 
to persistent psychosocial stress, or ruminating over past or future stressors, levels of 
inflammation can increase in the periphery and in the brain (Figure 7).133,134 Theoretically, 
this increased inflammation, may induce a biphasic shift in sleep patterns—initially, sleep 
continuity is increased in an effort to restore homeostasis (not illustrated); then later, sleep 
continuity is decreased paired with an increase in sleep architecture disturbances.135,136 Due 
to the bi-directional relationship between sleep and the immune system, prolonged sleep 
disturbance may shift molecular and protein profiles to those with increased inflammatory 
expression.136 Figure 7 illustrates how this chronic inflammatory state might contribute to 
the maintenance of PTSD (including its resistance to treatments) and explain its high 
comorbidity with other mental and physical health conditions.137 Furthermore, PTSD 
triggers may create a vicious feedback cycle and compound symptoms. Therefore, 
interventions that target the reciprocal sleep–immune relationship may have the potential to 
redirect this askew inflammatory expression and reduce stress-related symptoms. 
 
 
Figure 7 | Proposed model of how psychosocial stress may contribute to disease states. CRP, 
C-reactive protein; IL, interleukin; NF-κB, nuclear factor-kappa B; PTSD, posttraumatic stress 
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1.5.2 Sleep-focused treatments 
As new evidence points to sleep disturbance as a predictor of PTSD onset and relapse, 
sleep-focused treatments may be an effective and systemic means to mitigate posttraumatic 
stress symptoms, as well as the putative underlying inflammation. Sleep-focused treatments 
may also be preferred to trauma-focused psychotherapies due to the stigma associated with 
mental health issues, especially by military personnel.138 Cognitive behavioral therapy for 
insomnia (CBT-I) is a first-line treatment for insomnia, which targets maladaptive sleep-
related thought patterns and behaviors.139 A 2015 meta-analysis (N = 2189) reported that 
36% of insomnia participants who received CBT-I were in remission from insomnia and the 
CBT-I had similar positive effects on co-occurring mental and physical health symptoms.140 
Although these results are promising, a sizable percentage of the population still remained 
symptomatic. This highlights the need to investigate the efficacy of alternative 
interventions that target stress, sleep, and inflammation, directly or indirectly. 
 
1.5.3 Mindfulness meditation programs 
Mindfulness is a type of meditation with roots in an ancient Buddhist practice called 
Vipassanā.141 In a research context, mindfulness is typically defined as paying attention in a 
particular way: on purpose, in the present moment, and non-judgmentally.142 In recent 
years, mindfulness meditation has gained interest as a transdiagnostic intervention linked to 
improvements in various mental and physical health outcomes.143 In clinical trials, 
mindfulness-based stress reduction (MBSR) is the most popular mindfulness-based 
intervention tested; it includes eight weekly, 2.5-hour in-class sessions with daily 
homework exercises. Modified courses have since been created, such as mindfulness-based 
cognitive therapy (MBCT), a hybrid of MBSR and CBT. Mindfulness meditation is 
hypothesized to target brain regions implicated in cognition and emotional regulation.144 It 
has been shown to decrease emotional reactivity, diminish ruminative thoughts, and 
facilitate the impartial reappraisal of salient events.145-148 Systematic reviews have reported 
tentative evidence that mindfulness meditation reduces physiological markers of stress, 
blood levels of CRP, and expression levels of NF-κB.149,150 Several meta-analyses have 
investigated the effect of mindfulness meditation on sleep quality; however, the results have 
been inconclusive.151-153 Of these, the most robust meta-analysis reported insufficient 
evidence to draw any conclusions due to the limited number of available trials (n = 8) at the 
time of publication in 2014.153 Since then, there has been an exponential growth in 
mindfulness research, thus its potential effect on sleep quality warrants another review. 
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1.5.4 Integrative medicine programs 
Integrative medicine programs include mindfulness practices, but also make use of other 
conventional and alternative evidence-based methods to support the body's innate healing 
response using the least invasive methods as appropriate (Figure 8).154 Integrative medicine 
is patient-centered care that goes beyond the treatment of the initial symptoms and aims to 
address all potential causes and consequences of disease.155 This has important implications 
for military service members who often present with chronic conditions, including the 
signature polytrauma triad of chronic pain, mTBI, and PTSD.156 Several theoretical models 
of integrative medicine have been proposed depicting putative mechanisms of action. The 
most commonly-cited include the emphasis on the mindbody connection and the patient-
practitioner alliance and their collaboration in designing and implementing a 
comprehensive treatment plan.157 Unlike more robust clinical trials, which attempt to 
control for extraneous factors (by randomizing and blinding etc.), integrative medicine 
leverages a patient’s preferences, perspectives, and beliefs, as well as the patient-
practitioner relationship to enhance the effect of the intervention.158 As such, the outcome 
does not occur in isolation from the extraneous factors, but in synergy with them. 
Investigation of the program’s effectiveness typically treats the program as a synergistic 
bundle without dissecting the program components.158 
 
 
Figure 8 | The Wheel of Health - The Osher Center for Integrative Medicine, Vanderbilt 
University Medical Center. The Wheel of Health illustrates the integrative approach to healing 
and wellness. It is patient-centered and complements traditional care with additional therapies 
that are backed by scientific evidence to improve health and promote healing. © 2015 Vanderbilt 
University Medical Center. Reprinted with permission. 
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2 STUDY AIMS 
The general aim of this thesis was to examine the inextricable link between stress, sleep, 
and inflammation, and how gaining a better understanding of these interconnected systems 
could be harnessed to develop enhanced treatments for populations with stress-related 
symptoms and disorders. The aims for each study follow. 
 
STUDY I investigated the effect of 4 to 8 weeks of CBT-I and automatic positive 
airway pressure (APAP) therapy on posttraumatic stress symptoms, as 
well as the gene expression pathways that may mediate this effect in 
sleep disturbed military service members with and without PTSD. The 
secondary aim was to determine the gene expression profiles that were 
associated with each of the three PTSD symptom clusters: intrusions, 
avoidance/numbing, and arousal symptoms. 
STUDY II was a meta-analysis that assessed the effect of mindfulness meditation 
on sleep quality outcomes when compared to specific active controls 
(i.e., evidence-based sleep treatments) and nonspecific active controls 
(i.e., time/attention matched placebo controls) in sleep disturbed adults 
with a mental and physical health condition. The secondary aims were to 
assess for a long-term effect at 5- to 12-month follow-up and assess for a 
dose-response relationship between in-class meditation hours and sleep 
quality improvements. 
STUDY III investigated if sleep quality improvements, following a 4-week 
mindfulness-based integrative medicine program, were associated with 
reductions in posttraumatic stress (primary outcome), anxiety, 
depression, and postconcussion symptoms in sleep disturbed military 
service members with mTBI. The secondary aim was to determine if 
sleep quality improvements were associated with decreases in plasma 
levels of IL-6, IL-10, and TNF-α. 
STUDY IV investigated the effect of a brief 5-week (7.5-hour) mindfulness-based 
program on perceived stress symptoms in moderately stressed healthcare 
professionals. Secondary outcomes included burnout, anxiety, positive 
and negative affect, state and trait mindfulness, and self-care. 












In the great drama of existence, 
We are audience and actors at the same time. 
 
― Niels Bohr 
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3 METHODS 
This thesis included a range of methods and a comprehensive account can be found in the 
corresponding manuscripts (see Chapter 9. Appendix). Sleep-focused interventions were 
complemented with mechanistic studies of molecular and protein biomarkers. Since 
participant enrollment for this thesis began in 2013, the DSM-IV definition of PTSD is 
consistently used throughout all relevant studies. In Study I and Study III a combination of 
polysomnography, clinician assessed, and self-report measures were used to determine 
sleep disturbance. In Study II both actigraphy and self-report measures of sleep quality 
were used, but due to the insufficient number of studies that reported on actigraphy data (n 
= 2), only the self-report measures of sleep quality were included in the meta-analysis. An 
overview of the study design, population, intervention, outcomes, and main statistical test 
for each study is presented in Table 2. 
 
Table 2 | Overview of study characteristics. 
 STUDY I STUDY II STUDY III STUDY IV 
Study 
Design 
Case-Control Meta-Analysis Observational Randomized 
Clinical Trial 
Population Sleep disturbed 
military service 
members with or 
without PTSD 
Sleep disturbed 
adults with a mental 









Groups PTSD = 39 
No PTSD = 27 
Meditation = 917 
Control = 865 
Intervention = 93 Meditation = 43 
Control = 35 



















Not included Plasma IL-6, IL-




ANOVA Hedges’ g Linear regression GLMM 
ANOVA, analysis of variance; APAP, automatic positive airway pressure; CBT-I, cognitive behavioral 
therapy for insomnia; GLMM, generalized linear mixed models; IL, interleukin; PTSD, posttraumatic 
stress disorder; mTBI, mild traumatic brain injury; TNF-α, tumor necrosis factor-alpha 
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3.1 STUDY I: METHODS 
Study Design 
This was a case-control study that investigated the effect of 4 to 8 weeks of CBT-I and 
APAP therapy on posttraumatic stress symptoms, as well as the gene expression pathways 
that may mediate this effect in sleep disturbed military service members with and without 
PTSD. At baseline, participants diagnosed with insomnia received 4 to 8 biweekly sessions 
of CBT-I, and participants diagnosed with obstructive sleep apnea received APAP therapy. 
Baseline (week 1) and follow-up (week 12) visits included a battery of self-report 
questionnaires and blood draws. 
 
Participants 
Participants were characterized using the PTSD Checklist—Military Version (PCL-M).159 
Participants with a baseline PCL-M score ≥ 50 formed the PTSD group (n = 39) and 
participants with a baseline PCL-M score ≤ 25 formed the control group (n = 27); these are 
the proposed cut-points for military prevalence.160 At follow-up, the PTSD group was 
further divided into two groups: PTSD improved (n = 12; PCL-M change score reduction ≤ 
-5) and PTSD not-improved (n = 11; PCL-M change score ≥ 0).161 
 
Biomarker Acquisition 
Blood was collected into PAXgene tubes (PreAnalytiX Inc.; Hombrechtikon, Switzerland) 
and stored at −80 °C until RNA extraction using the PAXgene Blood RNA Kit. Samples 
were reverse transcribed using the GeneChip 3′ IVT Expression Kit and hybridized to 
Affymetrix HG-U133 Plus 2.0 microarrays (Affymetrix Inc.; Santa Clara, CA, USA). 
 
Statistical Analysis 
Analysis of variance (ANOVA) was used to compare baseline gene expression data 
between groups and paired t-tests were used to compare baseline to follow-up gene 
expression changes within groups. PCL-M symptom cluster subgroups were created using 
equal 33.33 percentile cut-points, whereby participants who endorsed the highest symptoms 
(high 1/3) were compared with participants who endorsed the lowest symptoms (low 1/3). 
Data were analyzed at a ± 2.0-fold change magnitude at a false discovery rate ≤ 0.05 using 
Partek Genomics Suite 6.6 (Partek Inc.; St. Louis, MO, USA). This criterion was 
determined by a power analysis indicating that the given ANOVA at a ± 2.0-fold change 
magnitude, would require 35 samples total for a beta of 0.80.162,163 All gene lists were then 
uploaded into the Ingenuity Pathway Analysis (QIAGEN; Redwood City, CA, USA). 
Stress, Sleep, and Inflammation 
 23 
3.2 STUDY II: METHODS 
Systematic Search 
This was a meta-analysis that assessed the effect of mindfulness meditation on sleep quality 
outcomes when compared to specific active controls (i.e., evidence-based sleep treatments) 
and nonspecific active controls (i.e., time/attention matched placebo controls) in sleep 
disturbed adults with a mental or physical health condition. PubMed, EBSCO, Embase, and 
The Cochrane Library databases were searched for articles through May 2018, with no start 
date restriction. For search terms, two main subject-heading domains were combined with 
the AND operator: one to designate the intervention (meditation, mindfulness, MBSR, 
MBCT, or Vipassanā) and the second to designate the outcome (sleep or insomnia). 
 
Inclusion and Exclusion Criteria 
Randomized controlled trials were included in the meta-analysis that enrolled populations 
of sleep disturbed adults and employed a mindfulness meditation intervention with sleep 
quality assessments at baseline and postintervention. Evidence-based sleep treatments were 
determined by an American Academy of Sleep Medicine 2006 report and updated with a 
2015 meta-analysis reporting medium to large effects of physical activity on subjective 
measures of sleep quality.164,165 Validated sleep measures included both objective and 
subjective measures. Trials were excluded that compared mindfulness meditation to an 
experimental sleep treatment or compared novice meditators to experienced meditators. All 
other populations with clinically significant sleep disturbance, excluding children and 
adolescents, were eligible (Table 3). 
 
The Strength of the Body of Evidence 
To determine the strength of the body of evidence, three investigators graded the strength of 
evidence for each outcome using the grading scheme recommended by the Methods Guide 
for Conducting Comparative Effectiveness Reviews.166 In assigning evidence grades, four 
domains were considered: risk of bias, directness of outcome measures, consistency of 
results, and precision of results. Evidence was classified into the following four categories: 
(1) high confidence that the estimate of effect lies close to the true effect, and further 
studies would not change the conclusion; (2) moderate confidence that the estimate of 
effect lies close to the true effect, and findings are likely to be stable, but some doubt 
remains; (3) low confidence that the estimate of effect lies close to the true effect, and that 
additional evidence is needed; and (4) insufficient or no evidence to estimate an effect.166 
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Table 3 | Detailed inclusion and exclusion summary. 
 Inclusion Exclusion 
POPULATION Adult populations with clinically 
significant sleep disturbance (i.e., 
insomnia diagnosis or met symptom 
severity threshold defined by sleep 
quality questionnaires) 
Children, adolescents, and experienced 
meditators 
INTERVENTION In-person, structured mindfulness 
meditation (e.g., mindfulness-based 
stress reduction) 
Mantra-based meditation, movement-
based therapies like tai chi, and 
internet administration 
COMPARATOR Specific active controls: 
evidence-based sleep treatments 
 
Nonspecific active controls: 
time /attention-matched interventions 
Waitlist or usual care controls 
OUTCOME Assessment of a baseline and 
postintervention validated objective or 
subjective measure of sleep quality 
No validated measure of sleep quality 
or only a baseline measurement 
STUDY DESIGN Randomized controlled trials Non-randomized controlled trials 
OTHER All languages and dates through May 
2018 
Abstracts, reviews, and 
non-published trials, as well as 
duplicate participant samples 
Adapted from “The effect of mindfulness meditation on sleep quality: a systematic review and 
meta-analysis of randomized controlled trials”, by H. L. Rusch, et al., 2018, Annals of the New 




Objective measures of sleep quality included actigraphy. Subjective measures with 
established validity included the Insomnia Severity Index (ISI), the Medical Outcomes 
Study—Sleep Scale (MOS-SS), and the Pittsburgh Sleep Quality Index (PSQI).167-169 Due 
to the high overlap in content validity between the three sleep quality scales, they were 
pooled in the meta-analysis. 
 
Statistical Analysis 
Quantitative data were analyzed with the Cochrane Collaborative Review Manager 
Software (RevMan 5.3).170 Since sleep quality measures differed between trials (e.g., ISI, 
MOS-SS, and PSQI), the between-group standardized mean difference was used as the 
summary effect estimate of sleep quality and was calculated as Hedges’ g. A meta-analysis 
was used to estimate the long-term effects of trials with a follow-up assessment between 5 
to 12 months from baseline. To test for relative efficacy, all meta-analyses were stratified 
by control type (i.e., specific active control or nonspecific active control). Spearman’s 
correlation was used to test for a dose-response relationship between in-class meditation 
hours and standardized sleep quality change scores. 
 
Stress, Sleep, and Inflammation 
 25 
3.3 STUDY III: METHODS 
Study Design 
This was an observational study that investigated if sleep quality improvements, following 
a 4-week mindfulness-based integrative medicine program, were associated with reductions 
in neurobehavioral symptoms and decreases in levels of inflammatory biomarkers in sleep 
disturbed military service members with mTBI. Participants underwent a 4-week intensive 
outpatient program that combines conventional rehabilitation therapies with complementary 
wellness interventions. The wellness interventions included acupuncture, biofeedback, 
creative arts therapy, and mindfulness practices (e.g., breathing, meditation, yoga). All 
interventions were administered by credentialed providers. Baseline (week 1) and follow-up 
(week 4) visits included a battery of self-report questionnaires and blood draws. 
 
Participants 
A total of 98 military service members consented for this study and 93 met eligibility 
criteria. Inclusion criteria included active military service members, 18 years of age or 
older, who sustained combat- or mission-related mTBI, with sleep disturbance. Exclusion 
criteria included a positive urine pregnancy test (for individuals with childbearing potential) 
and an inability to consent. The Ohio State University, Traumatic Brain Injury 
Identification Method (OSU TBI-ID) was used to diagnose mTBI, and the Pittsburgh Sleep 
Quality Index (PSQI) was used to measure baseline and follow-up sleep quality, and screen 
for self-reported sleep disturbance over the prior month.167,171 To provide the maximum 
sensitivity (0.90) and specificity (0.87), a total PSQI score of six or more indicated a 
positive screen for disturbed sleep. Five military service members did not have sleep 
disturbance based on a PSQI score of six or more and were considered ineligible. 
 
Outcome Measures 
The primary outcome, the PTSD Checklist—Military Version (PCL-M), was used to assess 
self-reported posttraumatic stress symptoms.159 Secondary self-report outcomes included 
the General Anxiety Disorder 7-Item (GAD-7), to assess anxiety; the Patient Health 
Questionnaire 9-Item (PHQ-9), to assess depression; and the Neurobehavioral Symptom 
Inventory 22-Item (NSI-22), to assess postconcussion symptoms.172-174 
 
Biomarker Acquisition 
Blood samples were collected through routine venipuncture into ethylenediaminetetraacetic 
acid tubes then aliquoted on ice into cryovials. The cryovials were stored upright in a 
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−80°C freezer until assayed. The Single Molecule Array HD-1 Analyzer (SIMOA; 
Quanterix, Billerica, MA) was used to measure plasma levels of inflammatory biomarkers 
using manufacturer’s instructions, consumables, and reagents. The SIMOA’s digital 
technology increases sensitivity by 1,000-fold on average over conventional 
immunoassays.175 Multiplex technology simultaneously quantified IL-6, IL-10, and TNF-α 
in one kit. Samples were batched assayed to minimize variability, and standards and 
controls were run with each batch to confirm reliability. All samples were analyzed in 
duplicate and all values were above the limit of detection. Samples were rerun when 
coefficients of variance exceeded 20%. Data were not used if coefficients of variance were 
above 20% after rerun, and intra-assay or inter-assay performance was below 20%. 
 
Statistical Analysis 
Statistical analyses were performed using the statistical software R (Version 3.3.3 for Mac; 
R Core Team, Vienna, Austria) and SPSS (Version 26 for Mac; IBM Corp, Chicago, IL). 
Categorical variables were described in frequencies and percentages and compared with 
chi-square tests, while continuous variables were described in means and standard 
deviations and compared with unpaired or paired t-tests as appropriate. Results were similar 
with and without the outliers, so all available data were included. All tests were two-sided 
and a p-value less than 0.05 was considered to be statistically significant. Linear regression 
models were used to assess the association between change in sleep quality (from baseline 
to follow-up) and change in neurobehavioral symptom severity and change in levels of 
inflammatory biomarkers over this same 4-week period. For example, the posttraumatic 
stress regression model included PSQI_Change as the predictor variable and PCL-
M_Change as the dependent variable, while also adjusting for PSQI at baseline, PCL-M at 
baseline, age, body mass index, race, tobacco use, and alcohol use. In a subgroup analysis, 
we conducted repeated-measures ANOVAs to investigate group differences between 
participants with improved sleep quality and those with declined sleep quality on changes 
in dependent variables found to be significantly associated with sleep from the main 
analysis. A three-point reduction on the PSQI is considered the minimal clinically 
important difference and was used to distinguish participants with improved sleep quality 
(PSQI change score ≤ -3) from those with declined sleep quality (PSQI change score ≥ 
1).176 Lastly, missing data patterns (e.g., participants who missed follow-up assessments 
due to lack of time) were examined with sensitivity analyses, based on imputation, for their 
impact on model inferences. 
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3.4 STUDY IV: METHODS 
Study Design 
This was a randomized clinical trial that investigated the effect of a brief 5-week (7.5-hour) 
mindfulness-based program on perceived stress symptoms in moderately stressed 
healthcare professionals. Participants were randomized into the mindfulness-based self-care 
(MBSC) group or the life-as-usual control group. The MBSC group attended five 1.5-hour 
mindfulness sessions at the National Institutes of Health, Clinical Center during work 
hours. Mindfulness exercises included mindful breathing, body scan, mindful walking, 
mindful movements, mindful eating, and loving-kindness meditation. Daily at-home 
mindfulness practice was strongly encouraged. Baseline (week 1) and postintervention 
(week 5) visits included a battery of self-report questionnaires for both groups, as well as a 
follow-up (week 13) visit for the MBSC group only to test for a maintenance effect. 
 
Participants 
Participation was open to all National Institutes of Health employees, contractors, and 
training fellows. Individuals with psychiatric and medical conditions were advised to 
consult with their healthcare providers before enrollment. Two participants in each group 
declined to participate after randomization, before the start of the study and did not provide 
baseline data. Thus, the modified intent-to-treat analyses included 43 meditation 
participants and 35 controls (Figure 9). 
 
Outcomes 
The primary outcome, the Perceived Stress Scale 10-Item (PSS-10) was used to assess self-
reported stress.177 Secondary self-report outcomes included the Visual Analog Scale—
Anxiety (VAS-A) to assess anxiety, the Maslach Burnout Inventory 2-Item (MBI-2) to 
assess burnout, the Positive and Negative Affect Schedule (PANAS) to assess positive and 
negative affect, the Mindful Attention Awareness Scale—Trait and State (MAAS-T and 
MAAS-S) to assess trait and state mindfulness, and the Mindful Self-Care Scale—General 
(MSCS-G) to assess mindfulness self-care practices.178-182 
 
Statistical Analysis 
Sample size was determined by calculating the power to detect a mean change score of 1-
point in perceived stress (PSS-10) between the meditation and control groups from baseline 
to postintervention.183 Estimates assumed a moderate-to-strong correlation (rho = 0.5) in 
the repeated measures, equal group allocation, two-sided alpha of 0.05, beta of 0.90, and an 
Heather L Rusch 
 28 
attrition rate of 10 to 15%, which yielded 33 participants per group. Generalized linear 
mixed modeling for repeated measures compared postintervention and follow-up measures 
between and within the meditation and control groups, as applicable. Mixed models are the 
recommended statistical method for analyzing data collected at repeated time points.184 
This method has the advantage of making use of all available data, accounting for within-
subject correlations between repeated measurements, and implicitly accounting for data 
missing at random. Post-hoc pairwise comparisons were adjusted for multiple comparisons 
using the Bonferroni method and reported p-values were corrected for multiplicity. Effect 
sizes were bias corrected with Cohen’s d and Hedges’ g. 
 
 
Figure 9 | CONSORT flow diagram. The study flow starting at enrollment and continuing 
through randomization, postintervention, and follow-up. MBSC, mindfulness-based self-care; ITT, 
intent-to-treat. Adapted from “Effect of a brief mindfulness-based program on stress in health care 
professionals at a US biomedical research hospital: A randomized clinical trial”, by R. Ameli, et 




82 Assessed for 
eligibility 
37 Assigned to Life as Usual 
     35 Per randomization 
       2 Declined participation 
45 Assigned to MBSC Intervention 
     43 Per randomization 
       2 Declined participation 
82 Randomized 
0 Lost at postintervention (week 5) 
Included in the ITT analysis 
     43 At postintervention (week 5) 
     43 At follow-up (week 13) 
5 Lost at postintervention (week 5) 
3 Lost at follow-up (week 13) 
    Reasons: 
x family emergency 
x illness 
x shift change 
x work obligations 
Included in the ITT analysis 
     35 At postintervention (week 5) 
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4 RESULTS 
Each study included a series of main and sub-analyses. This section briefly describes the 
results for each study; a comprehensive account can be found in the corresponding 
manuscripts (see Chapter 9. Appendix). An overview of the main findings for each study is 
presented in Table 4. 
 
Table 4 | Overview of study results. 
STUDY I 
Posttraumatic stress symptom reduction, following 4 to 8 weeks of 
CBT-I and APAP therapy, was linked to downregulated cell-mediated 
immune response genes and immune cell trafficking genes.a  
STUDY II 
Mindfulness meditation is an effective treatment to improve sleep 
quality in adult populations with various mental and physical health 
conditions. 
STUDY III 
Sleep quality improvements, following a 4-week mindfulness-based 
integrative medicine program, were linked to reductions in 
posttraumatic stress symptoms, but not to decreases in inflammation. 
 STUDY IV 
A brief 5-week (7.5-hour) mindfulness-based program reduced 
perceived stress in moderately stressed healthcare professionals. 





a Downregulation is the process by which a cell decreases the quantity of mRNA transcripts associated with a 
particular gene. Upregulation is the complementary process. The terms underexpression and overexpression 
are used synonymously. 
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4.1 STUDY I: RESULTS 
Study I investigated the effect of 4 to 8 weeks of CBT-I and APAP therapy on 
posttraumatic stress symptoms, as well as the gene expression pathways that may mediate 
this effect in sleep disturbed military service members with and without PTSD. The 
baseline demographic and clinical characteristics for the PTSD and control groups are 
presented in Table 5. 
 
Table 5 | Baseline demographic and clinical characteristics. 
 PTSD 
(n = 39) 
Controls 
(n= 27) 
x² / t p-value 
Age: n (%) 
18 – 35 years 


















































Body mass index: mean (SD) 29.8 (4.4) 29.6 (3.9) -0.196 0.846 
Complex insomnia: n (%) 18 (46.2) 3 (11.1) 9.031 0.003 
mTBI diagnosis: n (%) 29 (74.4) 1 (3.7) 32.125 < 0.001 
PTSD severity: mean (SD) 61.3 (7.7) 21.7 (2.7) -25.552 < 0.001 
mTBI, mild traumatic brain injury; PTSD, posttraumatic stress disorder 
 
The first gene expression analysis indicated that, at baseline, 89 genes were differentially 
expressed between participants with and without PTSD. Most of these genes (94%) were 
upregulated in the PTSD group. The next analysis compared the gene expression 
differences, also at baseline, between participants who endorsed high vs. low symptom 
severity among the three PTSD symptom clusters (see Table 1 for review). The purpose of 
this analysis was first to see if certain genes were associated with specific posttraumatic 
stress symptoms and secondly to see if a more robust gene expression profile would emerge 
for the intrusion symptom cluster (e.g., reexperiencing, nightmares, and flashbacks) since 
these are hallmark features of PTSD. As such, the gene expression analysis indicated that 
1040 genes were differentially expressed between participants with high vs. low intrusion 
symptoms. Most of these genes (98%) were upregulated in the high intrusion symptom 
group. There were no differentially expressed genes between participants with high vs. low 
avoidance/numbing symptoms or with high vs. low arousal symptoms. 
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Of the PTSD participants, 22.6% had clinically meaningful improvements (change score 
reduction ≤ -10).b The final analysis sought to determine which genes were associated with 
symptom improvement in this group. Herein, the gene expression analysis indicated that 18 
genes were differentially expressed in the PTSD group with improved symptoms from 
baseline to follow-up. All 18 genes’ were downregulated at follow-up and ten of these genes 
intersected with the PTSD vs. control differentially expressed gene list and the high vs. low 




Figure 10 | PTSD associated differentially expressed genes. (A) Venn diagram of differentially 
expressed genes between analyses. The PTSD and high intrusion symptom associated genes were 
mostly upregulated (94% and 98%), whereas the PTSD improved associated genes were all 
downregulated. (B) Ten overlapping differentially expressed genes between all three analyses with 
fold change score depicting the overexpression associated with posttraumatic stress symptoms and 
underexpression associated with posttraumatic stress symptom reduction. Adapted from “Gene 
expression differences in PTSD are uniquely related to the intrusion symptom cluster: a 
transcriptome-wide analysis in military service members”, by Rusch, H. L., et al., 2019, Brain, 
Behavior, and Immunity, 80, p. 906. © 2019 by Elsevier Inc. Adapted with Permission. 
 
The differentially expressed gene lists from the three analyses (see Figure 10) were then 
uploaded into Ingenuity Pathway Analysis to calculate the top physiological systems and 
networks linked with each gene expression comparison. Briefly, immune response and 
immune cell trafficking systems were upregulated in the PTSD group and high intrusion 
symptom group at baseline, which were downregulated with posttraumatic stress symptom 
improvement at follow-up. Downregulated networks of lipid metabolism, nucleic acid 
metabolism, and small molecule biochemistry, with an NF-κB hub, were linked to PTSD 
symptom improvement following the CBT-I and APAP therapy (Figure 11). 
 
 
b All participants with PTSD were included in this analysis, not only the participants with both baseline and 
follow-up gene expression data. 
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Figure 11 | Ingenuity pathway analysis. Ten genes (green) related to PTSD symptom 
improvement were linked to downregulated networks of lipid metabolism, nucleic acid 
metabolism, and small molecule biochemistry, with a nuclear factor kappa-beta (NF-κB) hub 
(blue). Reprinted from “Gene expression differences in PTSD are uniquely related to the 
intrusion symptom cluster: a transcriptome-wide analysis in military service members”, by 
Rusch, H. L., et al., 2019, Brain, Behavior, and Immunity, 80, p. 906. © 2019 by Elsevier Inc. 
Reprinted with Permission. 
 
4.2 STUDY II: RESULTS 
Study II was a meta-analysis that assessed the effect of mindfulness meditation on sleep 
quality. Eighteen trials with 1654 participants met the inclusion criteria and were included 
in the meta-analysis. In-class meditation sessions ranged from 1 to 2.5 hours per week for 2 
to 16 weeks. Meditation practice was encouraged at home in all 18 trials; however, 12 trials 
specified a practice time, which ranged from 15 to 60 minutes daily. Seven trials offered a 
full-day silent meditation retreat, and one trial offered an in-class booster session two 
months following the completion of the main program. 
 
The evidence suggests that mindfulness meditation is an effective treatment to improve 
sleep quality in adult populations with various mental and physical health conditions. Seven 
trials compared mindfulness meditation to evidence-based sleep treatments, such as CBT-I 
or medication for insomnia.185-191 The results indicated that mindfulness meditation had a 
similar effect on sleep quality compared to the evidence-based sleep treatments at 
postintervention (ES -0.03 [95% CI -0.49 to 0.43]) and at a 5- to 12-month follow-up (ES -
0.14 [95% CI -0.62 to 0.34]). However, the strength of this evidence was low due to the 
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high heterogeneity at both timepoints, and further studies are needed to confirm these 
results (Figure 12A). Eleven trials, compared mindfulness meditation to time/attention 
matched placebo controls.192-202 The results indicated that mindfulness meditation was 
superior to the time/attention matched placebo controls at postintervention (ES 0.33 [95% 
CI 0.17 to 0.48]) and at a 5- to 12-month follow-up (ES 0.54 [95% CI 0.24 to 0.84]). The 
strength of this evidence was moderate, indicating that the findings are likely to be stable, 




Figure 12 | Between-group relative percent difference in change score for (A) evidence-
based sleep treatments and (B) time/attention matched placebo controls. Author, year, and 
sleep scale are noted at the bottom of each cluster bar. Follow-up scores are reported for trials 
with a follow-up assessment between 5 and 12 months from baseline. Percent change in sleep 
score was calculated using the formula: {[(postintervention meancontrol − baseline meancontrol) − 
(postintervention meanmeditation − baseline meanmeditation)]/ (baseline meanmeditation) × 100}. 
Positive scores are the relative percent change in favor of meditation. For example, a change 
score of 20% indicates the meditation group had a 20% higher improvement in sleep quality 
score compared to the control group. *The result is statistically significant per manuscript. 
[*]Overall group effect is statistically significant. ISI, Insomnia Severity Index; MOS-SS, 
Medical Outcomes Study—Sleep Scale; PSQI, Pittsburgh Sleep Quality Index. Adapted from 
“The effect of mindfulness meditation on sleep quality: a systematic review and meta-analysis of 
randomized controlled trials”, by Rusch, H. L., et al., 2018, Annals of the New York Academy 
of Sciences, 1445(1), p. 11. © 2018 John Wiley & Sons, Inc. Adapted with permission. 
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Seventeen trials reported on in-class meditation hours for the total intervention, which 
ranged from 3 to 42 hours (15.6 mean, 9.8 SD), including the full-day retreat. There was no 
support for a dose-response relationship between in-class meditation hours and 
standardized sleep quality change scores. Six trials evaluated a dose-response relationship 
between at-home mediation practice and improvements in sleep quality from baseline to 
postintervention. Three trials found a significant positive correlation.185,189,202 While another 
three trials identified no relationship.187,191,194 
 
4.3 STUDY III: RESULTS 
Study III investigated if sleep quality improvements, following a 4-week mindfulness-based 
integrative medicine program, were associated with reductions in neurobehavioral 
symptoms and decreases in levels of inflammatory biomarkers in sleep disturbed military 
service members with mTBI. The demographic and clinical characteristics for the total 
sample are presented in Table 6. 
 





Variables, No. (%)   
Male sex 93 (100)  
White race 89 (95.7)  
Tobacco users 34 (36.6)  
Alcohol users 79 (84.9)  
PTSD Dx. 44 (47.3) 21 (22.6) 
Anxiety Dx. 60 (64.5) 22 (23.7) 
Depression Dx. 60 (64.5) 20 (21.5) 
Postconcussion syndrome Dx. 81 (87.1) 31 (33.3) 
Variables, mean (SD) 
Age, years 40.77 (5.35)  
Body mass index 28.56 (3.18)  
Total treatment, hours  29.24 (8.71) 
Creative arts therapy  9.77 (3.77) 
Mindfulness practices  6.93 (3.75) 
Other integrative practices  12.55 (7.03)  
All diagnoses (Dx.) are provisional based on self-report measures. 
 
From baseline to follow-up the sample as a whole had significant reductions in sleep 
disturbance (t73 = 6.449; p < 0.001), posttraumatic stress (t76 = 7.598; p < 0.001), anxiety 
(t76 = 11.077; p < 0.001), depression (t75 = 9.731; p < 0.001), and postconcussion symptoms 
(t76 = 10.684; p < 0.001), as well as decreases in levels of TNF-α (t82 = 3.246; p < 0.002). 
No significant change in levels of IL-6 or IL-10 were observed. The next analysis sought to 
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determine if there was an association between sleep quality improvements and change in 
neurobehavioral symptom severity and inflammatory biomarker levels. Herein the data 
indicated that improvements in sleep quality were significantly associated with reductions 
in posttraumatic stress (β = 1.286; [95% CI 0.689 to 1.883]; p < 0.001), anxiety (β = 0.568; 
[95% CI 0.322 to 0.814]; p < 0.001), depression (β = 0.761; [95% CI 0.504 to 1.017]; p < 
0.001), and postconcussion symptoms (β = 1.786; [95% CI 1.054 to 2.518]; p < 0.001) 
(Figure 13). Improvements in sleep quality were not directly associated with change in any 
of the inflammatory biomarker levels over this same 4-week period. 
 
 
Figure 13 | Associations between sleep quality improvements and change in posttraumatic 
stress symptoms. Change scores were calculated by subtracting the baseline (week 1) value from 
the follow-up (week 4) value, hence a negative value indicates a reduction in sleep disturbance 
and posttraumatic stress symptoms. PCL-M, PTSD Checklist—Military Version; PSQI, 
Pittsburgh Sleep Quality Index 
 
Following the 4-week integrative medicine program, 40.9% of participants reported 
clinically meaningful sleep quality improvements, 15.1% reported sleep quality declines, 
and 23.7% reported no meaningful difference in sleep quality. Of the PTSD participants, 
65.8% had clinically meaningful symptom reduction (change score reduction ≤ -10). For 
the subgroup analysis, participants with improved sleep quality (n = 38) were compared 
with participants with declined sleep quality (n = 14) to examine the putative role of sleep 
quality changes on neurobehavioral symptom severity. Herein, there were significantly 
larger reductions in posttraumatic stress (f1,44 = 13.621; p = 0.001), anxiety (f1,45 = 5.694; p 
= 0.021), depression (f1,44 = 8.605; p = 0.005), and postconcussion symptoms (f1,44 = 6.969; 
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Figure 14 | Change in neurobehavioral symptom severity from baseline to follow-up 
according to change in sleep quality. Change scores were calculated by subtracting the baseline 
(week 1) value from the follow-up (week 4) value, hence a negative value indicates a reduction 
in neurobehavioral symptoms. GAD-7, General Anxiety Disorder 7-Item; NSI-22, 
Neurobehavioral Symptom Inventory 22-Item; PCL-M, PTSD Checklist—Military Version; 
PHQ-9, Patient Health Questionnaire 9-Item. Data are depicted as mean change score and 
standardized mean error. 
 
4.4 STUDY IV: RESULTS 
Study IV investigated the effect of a brief 5-week (7.5-hour) mindfulness-based program on 
perceived stress symptoms in moderately stressed healthcare professionals. The baseline 
demographic and clinical characteristics for the meditation and control groups are presented 
in Table 7. The meditation group had a mean age in years (SD) of 35.7 (15.4) and the 
controls had a mean age in years (SD) of 36.4 (13.0). 
 
Table 7 | Baseline demographic and clinical characteristics. 
 
Variable, No. (%) 
Meditation 
(n = 43) 
Control 
(n = 35) 
Female sex 37 (86.1) 28 (80.0) 
Hispanic/Latinx 5 (11.9) 5 (14.3) 
Race 
































Medical condition 16 (37.2) 9 (25.7) 
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To test the effect of the brief 5-week (7.5-hour) mindfulness-based program, the meditation 
group was compared with the control group on their change in symptoms and behaviors 
from baseline (week 1) to postintervention (week 5). Herein, the meditation group had 
significantly larger reductions in perceived stress (∆ -2.50 [95% CI -4.28 to -0.72] vs. ∆ -
0.04 [95% CI -0.37 to 0.29]; p = 0.016) and anxiety (∆ -2.13 [-2.79 to -1.48] vs. ∆ -0.19 [-
0.53 to 0.14]; p < 0.001], as well as significantly larger increases in positive affect (∆ 2.94 
[0.70 to 5.18] vs. ∆ -0.33 [-0.68 to 0.02]; p < 0.001], state mindfulness (∆ 1.59 [1.17 to 
2.01] vs. ∆ 0.26 [-0.08 to 0.60]; p < 0.001), and mindfulness self-care practices (∆ 1.61 
[0.68 to 2.53] vs. ∆ -0.16 [-0.49 to 0.17]; p < 0.001) (Figure 15). There were no significant 
between-group differences in burnout, negative affect, or trait mindfulness. 
 
 
Figure 15 | Between and within-group Perceive Stress Scale-10 (PSS-10) score differences. 
The mindfulness-based self-care (MBSC) group had significantly larger reductions in perceived 
stress compared with the control group at postintervention (week 5) and these reductions were 
maintained through the follow-up assessment (week 13). Data are depicted as mean score and 
standardized mean error. 
 
The second analysis sought to determine if the meditation group maintained any potential 
benefits gained from the mindfulness-based program two months later. As such, from 
baseline (week 1) to follow-up (week 13), the meditation group had additional significant 
reductions in perceived stress (∆ = -6.14 [95% CI -7.84 to -4.44]; p < 0.001), maintained 
reductions in anxiety (∆ = -1.46 [-1.97 to -0.94]; p < 0.001), and had additional significant 
increases in state mindfulness (∆ = 1.89 [1.39 to 2.39]; p < 0.001) (Figure 15). The 
increases in positive affect and mindfulness self-care practices observed from baseline to 



















Controls (n = 35) MBSC (n = 43)
p < 0.001p = 0.009
p = 0.016












When you change the way you look at things, 
The things you look at change. 
 
― Max Planck 
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5 DISCUSSION 
The general aim of this thesis was to examine the inextricable link between stress, sleep, 
and inflammation, and how gaining a better understanding of these interconnected systems 
could be harnessed to develop enhanced treatments for populations with stress-related 
symptoms and disorders. The main findings, methodological considerations, clinical 
implications, and directions for future research are discussed. 
 
5.1 STUDY I: DISCUSSION 
Study I investigated the effect of 4 to 8 weeks of CBT-I and APAP therapy on 
posttraumatic stress symptoms, as well as the gene expression pathways that may mediate 
this effect in sleep disturbed military service members with and without PTSD. Results 
indicated that 22.6% of participants with PTSD had clinically meaningful posttraumatic 
stress symptom reduction following treatment (i.e., response rate). The average response 
rate for trauma-focused psychotherapy is between 49 to 70% in military populations.129 The 
lower response rate in our study seemed to be due to the high noncompliance rate to the 
APAP therapy. Typically, noncompliance rates of 20% or more pose serious threats to 
treatment efficacy—our noncompliance rate of 66.7% was three times greater than the 
accepted standard.203 Even though positive airway pressure therapies, including APAP 
therapy, are the most effective treatment for obstructive sleep apnea, compliance is 
challenging in populations with PTSD, and approaches to increase adherence are needed.204 
 
In the pathway analysis, genes associated with immune response systems were the most 
reliably upregulated pathways that distinguished participants with PTSD from those 
without PTSD. These results are supported by our prior transcriptome work (Paper 3) and 
the results from a mega-analysis of blood transcriptome studies (N = 511).119,205 Moreover, 
the current study extends these findings by showing that posttraumatic stress symptom 
reduction, following standardized sleep therapy, is associated with a downregulation of 
these same immune response systems. Despite this relationship, the direction of causality 
cannot be determined. It is also quite possible that sleep quality improvements reduced both 
the severity of posttraumatic stress symptoms and levels of inflammation simultaneously 
and independently. Within the same cohort (but not grouping by PTSD) we previously 
reported that participants with improved sleep quality, following standardized sleep 
therapy, had reduced expression of genes related to inflammatory cytokines with a trend 
reduction in posttraumatic stress symptoms (∆ = -3.1 [SD 1.2]; p < 0.067) (Paper 2).124 
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In Study I, we also found that gene expression differences between participants with and 
without PTSD were almost exclusively attributed to the intrusion symptom cluster (98%), 
and there were no gene expression differences associated with the remaining two symptom 
clusters. One justification for these findings is that intrusion symptoms (e.g., nightmares, 
flashbacks, and reexperiencing symptoms) are specific to PTSD, whereas pathological 
symptoms of avoidance/numbing and arousal overlap with other mental and physical health 
conditions common in military populations, most notably depression and mTBI (Figure 
16). If participants endorse PTSD-like symptoms that are due to co-occurring conditions—
for example, cognitive deficits incurred from mTBI—the same phenotypic expression 
might be represented by different underlying gene expressions and therefore mask between-
group differences. An alternative explanation could be that trauma exposure elicits gene 
expression alterations involved in intrusion symptoms, and secondary symptoms of 
avoidance, depression, hyperarousal, etc. develop in response. For example, flashbacks 
could cause an individual to avoid certain people and places in an effort to minimize 
trauma-related triggers and increase a sense of safety. It is also likely that the PTSD group 
in our study was comprised of false-positive cases—participants who met the PCL-M ≥ 50 
cutoff score by endorsing PTSD-like symptoms due to comorbid conditions. When these 
potentially false-positive cases were removed from the analysis, a more robust gene 
expression profile emerged. 
 
 
Figure 16 | Venn diagram of symptom overlap between posttraumatic stress disorder 
(PTSD) and mild traumatic brain injury (mTBI). Intrusion symptoms (e.g., reexperiencing, 
nightmares, and flashbacks) are specific to PTSD. Whereas avoidance/numbing symptoms (e.g., 
avoidance of people, places, and things that are trauma reminders and cognitive and mood 
alterations) and arousal symptoms (e.g., insomnia, irritability, and increased startle) overlap with 
other neurobehavioral conditions. Reprinted from “Gene expression differences in PTSD are 
uniquely related to the intrusion symptom cluster: a transcriptome-wide analysis in military 
service members”, by Rusch, H. L., et al., 2019, Brain, Behavior, and Immunity, 80, p. 906. © 
2019 by Elsevier Inc. Reprinted with Permission. 
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5.2 STUDY II: DISCUSSION 
In order to investigate alternative interventions that may improve sleep quality and 
potentially provide additional benefits for stress-related disorders, Study II conducted a 
meta-analysis to determine the effect of mindfulness meditation on sleep quality outcomes 
in sleep disturbed adults with various mental and physical health conditions. The results 
indicated that mindfulness meditation had a similar effect on sleep quality compared to the 
evidence-based sleep treatments and was superior to the time/attention matched placebo 
controls. The results also suggested that the benefits of mindfulness meditation were 
maintained for up to 5 to 12 months following the completion of the study. Mindfulness 
research is still in its infancy; however, these long-term effects may have been supported by 
sleep architecture changes, functional and structural brain alterations, or increased mastery 
of techniques that minimize sleep-disruptive emotional and cognitive processes.206-209 
Nevertheless, due to the high heterogeneity and modest number of studies that met our 
inclusion criteria, we had low to moderate confidence in these results, and further research 
is warranted to confirm our positive findings. 
 
We also found no evidence to support a dose-response relationship between in-class 
meditation hours and change in sleep quality. These results are echoed in a meta-analysis 
that evaluated the relationship between in-class meditation hours and change in 
psychological distress.210 Dose-response relationships are arguably one of the most difficult 
metrics in meditation research due to a number of factors. First, it is challenging to 
accurately assess how mindful (verse mind wandering) a participant is during meditation 
practice.211 Moreover, mediation progress has a multiphasic trajectory, which is often 
misunderstood in Western contexts.212 Traditionally, success in meditation is defined by 
increased awareness (sati) and equanimity (upekkhā), whereby positive mental and physical 
states are a byproduct. When symptom change over a brief period is the only benchmark of 
success, meditation progress and its potential effect on wellbeing may be veiled. 
 
5.3 STUDY III: DISCUSSION 
Once mindfulness meditation was established as a potential intervention to improve sleep 
quality, Study III investigated if sleep quality improvements, following a 4-week 
mindfulness-based integrative medicine program, were associated with reductions in 
posttraumatic stress, anxiety, depression, and postconcussion symptoms, as well as 
decreases in inflammation in sleep disturbed military service members with mTBI. Results 
indicated that 40.9% of participants reported clinically meaningful sleep quality 
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improvements, following the intervention, which were linked to reductions in posttraumatic 
stress and other neurobehavioral symptoms. These findings were also reflected in the 
subgroup analysis where we compared participants with improved sleep quality to 
participants with declined sleep quality on the same outcomes. At follow-up, 65.8% of 
participants with PTSD and 55% of the entire cohort had clinically meaningful reductions 
in posttraumatic stress symptoms. However, the response rates were quite diverse between 
the improved sleep group (60%) and the declined sleep group (14%). These findings 
suggest that improved sleep quality is involved in posttraumatic stress symptom reduction 
and extends this line of inquiry to include other neurobehavioral symptoms. Nonetheless, 
the study design tempers any conclusions regarding the direction of causality, and symptom 
reduction overall may be due to placebo effects or other factors. 
 
Next, we found a small, but significant decrease in levels of TNF-α over time; however, 
these reductions were not associated with improvements in sleep quality. Even though sleep 
plays an essential role in regulating the innate immune system, evidence of this direct 
relationship may not have been captured by our choice of sleep quality assessment (the 
PSQI self-report measure) or duration of study assessment (4-week period). In this respect, 
a comprehensive meta-analysis (N > 50,000), found that levels of inflammatory biomarkers 
such as CRP, IL-6, and TNF-α were subject to the diverse parameters used in clinical trials 
to assess sleep quality (e.g., objectively measured, clinician assessed, or self-reported), as 
well as the duration of sleep deprivation (e.g., years, days, one night, or part of a night).121 
It is also possible that the decreased levels of TNF-α may have been a downstream effect in 
response to a reduction in neurobehavioral symptoms and not in response to sleep quality 
improvements.118,213 Lastly, we cannot rule out that such observation was not due to diurnal 
variation or natural variation over time.214,215 We also did not observe significant changes in 
levels of IL-6 and IL-10 over time or in association with improvements in sleep quality. 
Sex differences are one possible reason for these findings.216 The current cohort was 
comprised solely of men and prior studies investigating human adult molecular and protein 
biomarkers have more often indicated stronger links between sleep disturbance and 
inflammation in women than in men.217,218 This sexual dimorphism is thought to be driven 
at least in part by the differences in reproductive hormones between the two sexes.218,219 
 
5.4 STUDY IV: DISCUSSION 
We found some evidence that posttraumatic stress symptoms were reduced in military 
service members following the mindfulness-based integrative medicine program; however, 
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this program required almost 30 treatment hours. This may be an excessive treatment 
duration when mindfulness meditation is used in populations with less severe symptoms. 
As such, Study IV investigated the effect of a brief 5-week (7.5-hour) mindfulness-based 
program on perceived stress symptoms in moderately stressed healthcare professionals. 
Results indicated that the meditation group had larger reductions in perceived stress and 
anxiety compared with the control group, and these reductions were maintained two months 
following the completion of the program. At present there are no recognized minimal 
clinically important difference scores for the PSS-10 (perceived stress) or the VAS-A 
(anxiety).c However, normative data from 2009 reported mean PSS-10 scores of 19.11 in 
high-stress groups and 11.09 in low-stress groups.220 In our meditation group, PSS-10 
scores reduced from 19.63 to 13.30 over the course of the study. Thus, we can extrapolate 
that the participants had some clinically meaningful level of stress reduction, although their 
levels may not have reached the threshold of low stress. However, it’s worth noting that the 
participants were self-motivating volunteers and may have been prone to an expectancy 
bias, which could have influenced the between-group effects.d We also found no significant 
between-group differences in burnout (i.e., emotional exhaustion and depersonalization), 
which may have been due to a floor effect since the participants did not present with high 
levels of burnout to begin with. Moreover, the use of the abridged 2-item MBI may not 
have captured the presentation of burnout in this population. 
 
Typical mindfulness-based programs are around 30 hours in duration and include a full-day 
silent meditation retreat. This can be cost prohibitive and impractical to implement during 
the workday in a bustling healthcare setting.221 When mindfulness-based programs are 
below four hours, the benefits are inconclusive.221 In the current mindfulness-based 
program, classes filled up within three days of the announcement, which was a proxy for 
community interest. The overall quality of the program was rated as ‘very good’ or 
‘excellent’ by 97% of the meditation participants. No adverse events were reported and the 
attrition rate of 19% was consistent with the literature for comparable populations.222 As 
such, these findings suggest that a brief 5-week (7.5-hour) mindfulness-based program is 
feasible and effective at reducing perceived stress and anxiety in healthcare professionals. 
 
 
c The minimal clinically important difference (MCID) defines the smallest amount an outcome must change to 
be meaningful to the patient. An outcome’s change can be statistically significant and not meet the MICD. 
 
d Expectancy bias is a type of cognitive bias that occurs when a participant expects a certain result and 
therefore unconsciously manipulates an experiment or reports the expected result. 
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5.5 GENERAL METHODOLOGICAL CONSIDERATIONS 
This thesis had a number of strengths and limitations; the main methodological 
considerations are discussed below, and a comprehensive account can be found in the 
corresponding manuscripts (see Chapter 9. Appendix). The first methodological 
consideration involves the inclusion/exclusion of randomized controlled trials. Randomized 
controlled trials are the gold standard for evaluating the effectiveness of an intervention. 
Herein, groups of similar people are randomly assigned to an experimental group or to a 
control group; the outcome variable of interest is the only expected difference between the 
two groups. However, due to ethical, feasibility, and financial reasons this study design is 
sometimes not a viable option. In Study II, we only included randomized controlled trials in 
the meta-analysis that compared mindfulness meditation to evidence-based sleep treatments 
or to time/attention matched placebo controls. This provided greater confidence that the 
reported benefits of mindfulness meditation were not due to nonspecific effects.e In Study 
IV, we randomized participants to either a meditation experimental group or a life-as-usual 
control group. Including an active control group would have strengthened our study; 
however, there is no consensus on what constitutes an ideal active control group for 
mindfulness meditation in non-clinical populations. Sham mindfulness meditation has been 
used with success for very short interventions (20 to 30 minutes).223 However, 
administering sham mindfulness meditation for longer programs over multiple sessions 
becomes challenging. In 2012, researchers attempted to validate the Health Enhancement 
Program (HEP) as an acceptable active control group for mindfulness mediation; herein all 
components of MBSR are matched in the HEP control group with the exception of 
mindfulness.224 While these types of studies are critical in evaluating the effectiveness of 
mindfulness meditation, they can be costly and timely to implement. For ethical reasons, 
Study I and Study III were not randomized controlled trials (it is unethical to deny 
treatment to symptomatic active duty military), thus we were limited in the conclusions we 
could make regarding the treatment effects for these studies. 
 
One way we attempted to compensate for the single-arm designs in Study I and Study III 
was to minimize clinical heterogeneity. Clinical heterogeneity arises from differences in 
participant demographics (e.g., sex, age, race), clinical characteristics (e.g., symptom 
 
 
e Nonspecific effects are the indirect benefits of the treatment, such as placebo effects and indirect benefits 
from the healthcare providers’ time and attention toward the participants. 
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severity, comorbidities), and intervention characteristics (e.g., type, duration, frequency, 
dose). This variability can lead to inaccurate conclusions and in turn mislead decision-
makers and other researchers. The participants in Study I and Study III were mostly white 
men under 57 years of age. Both studies were also comprised of military service members 
with sleep disturbance and neurobehavioral symptoms. However, in Study I the most 
conservative cut-points were used to create well-characterized groups of participants with 
and without PTSD. This allowed us to determine the differentially expressed genes that 
were specific to posttraumatic stress symptoms and symptom reduction with enhanced 
precision. In Study III, there was much greater heterogeneity in symptom severity and 
comorbidity. While most participants had some degree of neurobehavioral symptoms, only 
47 to 87% met criteria for a provisional diagnosis for at least one mental health condition 
(range dependent on the condition, see Table 6). This may have masked changes in IL-6 
and IL-10 over time that could have been linked to the improvement of a specific symptom 
or condition. Lastly, there was unintended heterogeneity in the intervention characteristics. 
In Study I, the participants were assigned a standardized sleep treatment based on their 
diagnosed sleep disorder; however, there was such a high noncompliance rate (66.7%) for 
the APAP therapy, it was difficult to draw any conclusions regarding treatment effects 
except that the APAP therapy was not feasible in participants with PTSD. In Study III, the 
participants, in collaboration with their practitioner, designed their own treatment plan; this 
personalized medicine approach is at the heart of integrative medicine but precluded us 
from testing for specific intervention effects. 
 
While clinical homogeneity has its strengths, it should be balanced with generalizability. 
Generalizability is the extent to which the conclusions of a study can be applied to broader 
groups of people and settings. Even though Study II had very strict inclusion/exclusion 
criteria when it came to intervention types and comparison groups, we were liberal in 
including all adult populations provided they had clinically relevant sleep disturbance and 
were not expert meditators (see Table 3). Since the final meta-analysis included adults with 
an array of mental and physical health conditions, there is greater confidence that the 
findings can be extended to other groups with sleep disturbance beyond those that were 
included in our study. Study I and Study III are limited in their ability to generalize the 
findings to women, civilians, and other non-military trauma types. Likewise, in Study IV, 
the results may not generalize to men, lower educational levels, or other institutes that do 
not value or emphasize the benefits of supporting employee health and wellness. 
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5.6 CLINICAL IMPLICATIONS & FUTURE DIRECTIONS 
PTSD can be difficult to diagnose because it shares symptoms with other mental and 
physical health conditions. When PTSD is misdiagnosed, patients do not receive the correct 
treatment, which can be inefficient and harmful. In Study I, we investigated what symptoms 
could genetically differentiate participants with PTSD from those without PTSD and found 
that intrusion symptoms accounted for almost all of the gene expression differences. 
Additionally, we found that intrusion symptoms were linked to increased expression of 
immune response genes, which were normalized with symptom reduction. This highlights 
the importance of focusing on the intrusion symptom cluster for precision medicine 
initiatives in individuals with PTSD. Since Study I was initiated, more advanced gene 
expression technologies like RNA sequencing are now available that are able to identify 
both known and unknown genes. A significant body of literature has also demonstrated that 
the protein and microRNA constituents of exosomes (small extracellular vesicles) hold 
promise as novel biomarkers for PTSD (Paper 5).225 This unveils exciting opportunities for 
improving diagnostics in trauma-exposed populations. Our ultimate goal is to design 
biomarker-based tests that will not only predict who will develop PTSD following a 
traumatic event but will also identify the most effective treatment for a given individual. 
 
Another avenue to help decrease the risk for PTSD and increase the effectiveness of 
treatments is through the early identification and treatment of sleep disturbance in trauma-
exposed populations. At present, there is no consensus about incorporating evidence-based 
sleep treatments into standard of care for the prevention or management of PTSD; 
importantly, there are no empirical data available to establish the order in which sleep and 
PTSD treatments should be delivered.226 One recent pilot study examined the delivery of 
CBT-I prior to trauma-focused psychotherapy in veterans and reported large decreases in 
insomnia and posttraumatic stress symptoms, and large increases in quality of life.227 
Moreover, clinicians need to be aware that sleep disturbance can diminish the efficacy of 
trauma-focused psychotherapy, especially when they rely on memory extinction and 
consolidation processes.99,228 Future studies might establish the efficacy of integrative 
medicine approaches that address sleep disturbances and posttraumatic stress symptoms 
simultaneously. For example, Study III combined soporific mindfulness practices with art 
therapy, which has a putative effect on PTSD trauma processing.229 Lastly, while APAP 
therapy may be more challenging for individuals with PTSD, research has found that 
enhanced self-efficacy can help increase compliance.230 
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In addition to evidence-based sleep treatments, alternative interventions that target multiple 
biological systems may offer additional benefits to individuals with stress-related disorders. 
Current first-line treatments for PTSD target psychological symptoms; however, the 
presence of immune response genes (Study I) suggests a need for a more comprehensive 
treatment approach to address the potential influences of immune dysregulation on emotion 
and behavior.231,232 It is possible that the growing interest in alternative therapies for PTSD 
such as meditation, yoga, and other interventions that increase physical activity or alter 
dietary intake may provide benefits through their anti-inflammatory effects.233-236 To date, 
at least 20 clinical trials have investigated the antidepressant activity of anti-inflammatory 
treatments on depressive symptoms in individuals with chronic inflammatory conditions.237 
Many of these trials reported significant reductions in symptoms of depression, which 
prompted a new series of clinical trials specifically designed to evaluate the safety and 
efficacy of anti-inflammatory therapeutics in mood disorders.238 This research opens up a 
new line of investigation for novel therapeutics that directly target inflammation in 
individuals with PTSD, which could potentially result in improved mental and physical 
outcomes. Future research would also benefit from empirical studies that examine the 
relationship between posttraumatic stress symptoms and inflammation dimensionally 
(along a spectrum from low to high) as outlined by the Research Domain Criteria. 
 
Lastly, mindfulness meditation may be beneficial to reduce perceived stress, which could 
potentially prevent the development of more severe mental and physical health conditions. 
In Study IV, the 7.5-hour mindfulness-based program was a feasible and effective level of 
training to reduce stress and anxiety in busy healthcare professionals. When stress is left 
unchecked it can increase the risk for burnout (see Figure 1). A systematic review of 36 
prospective trials found that burnout was a significant predictor of developing the following 
physical health conditions: cardiovascular disease, hypercholesterolemia, type 2 diabetes, 
respiratory issues, gastrointestinal problems, musculoskeletal pain, headaches, prolonged 
fatigue, and mortality under 45 years of age.239 Moreover, burnout increased the risk of 
developing insomnia, being hospitalized for a psychiatric disorder, and being prescribed 
psychotropic and antidepressant medications.239 Burnout not only affects the individual, but 
has been associated with decreased productivity, suboptimal patient care, and increased 
medical errors.240 To help ensure the safety of both provider and patient, organizations 
should work towards implementing feasible and effective interventions to build resilience 
in healthcare professionals, so they can better manage occupational challenges. 
 












If I have seen further, 
It is by standing upon the shoulders of giants. 
 
― Sir Isaac Newton 
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6 CONCLUSIONS 
The findings of these four studies led to some important conclusions regarding the link 
between stress, sleep, and inflammation that may inform the development of enhanced 
treatments for populations with stress-related symptoms and disorders. In Study II, while 
mindfulness research is still in its infancy, our preliminary results suggest that mindfulness 
meditation is effective in improving sleep in adult populations with various mental and 
physical health conditions. Less intense mindfulness meditation programs (7.5 hours) may 
be beneficial to reduce perceived stress, which could potentially prevent the development of 
more severe mental health conditions (Study IV). While 22.6% of individuals with PTSD 
had reduced posttraumatic stress symptoms following standardized sleep therapy (Study I), 
65.8% of individuals with PTSD had reduced posttraumatic stress symptoms following the 
mindfulness-based integrative medicine program (Study III). There was some evidence that 
a relationship exists between sleep quality improvements, decreases in gene expression 
levels of inflammation, and reductions in posttraumatic stress symptoms; although the 
direction of causality could not be determined (Study I and III). Despite these findings, the 
potential mediating role of inflammation between sleep disturbance and posttraumatic 
stress symptoms is still unclear. Future research would profit from addressing the 
outstanding methodological design limitations, in addition to testing for sex differences, 
and using a combination of objective and subjective measures of sleep in concert with 
molecular and protein biomarker assessments. The field of mindfulness and 
psychoneuroimmunology present great opportunities for therapeutic discovery to increase 
resilience to buffer stress-elicited changes in physiology including immune responses. 












A human being is a part of the whole, called by us “Universe”, a part limited in time and 
space. He experiences himself, his thoughts, and feelings as something separated from the 
rest—a kind of optical delusion of his consciousness. This delusion is a kind of prison for 
us, restricting us to our personal desires and to affection for a few persons nearest to us. 
Our task must be to free ourselves from this prison by widening our circle of compassion to 
embrace all living creatures and the whole of nature in its beauty. Nobody is able to 
achieve this completely, but the striving for such achievement is in itself a part of the 
liberation and a foundation for inner security. 
 
― Albert Einstein 
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Let yourself be silently drawn by the strange pull of what you really love. 
It will not lead you astray. 
 
― Rumi 
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